Prognose
Analytikernes gennemsnitlige kursmål er 14,97 € (+24,23 %). Medianen er 12,76 € (+5,89 %).
| Køb |
12 |
| Behold |
12 |
| Sælg |
4 |
Diskussioner i communityet
Der er endnu ingen diskussion om dette aktiv.
Start diskussionNyheder Til nyhedsfeedet
Integra LifeSciences: operational recovery accelerating, margin and cash improvement expected
At the Wells Fargo Healthcare Conference, Integra LifeSciences reported continued recovery from supply-chain and quality issues: production capacity in Braintree has been ramped up and product relaunches such as PriMatrix, Durepair and SurgiMend are on schedule. The company reaffirmed its organic 2026 growth guidance of 0.8–3.3%, expects roughly a 100 basis-point expansion in EBITDA margin and about $150 million in free cash flow for 2026. Sales focus is shifting from supply management to clinical consulting, new products like Liberties (neurosurgery) are planned for 2027, and M&A will remain secondary until the balance sheet is stabilized. » Mere på de.investing.com
Integra LifeSciences under upward pressure after Argus upgrade
The stock of Integra LifeSciences rose 1.9% pre-market after Argus upgraded its rating from 'hold' to 'buy' and set a $25 price target. Argus cited restored confidence in management, resolved production bottlenecks and more stable revenue growth as reasons. Integra also beat Q1 results and raised its full-year guidance; risks remain product recalls and high debt. » Mere på de.investing.com
Integra LifeSciences reaches 52-week high at $16.49
Integra LifeSciences stock rose to a 52-week high of $16.49, 85% above its yearly low of $8.70; year-to-date return is 22.3%. InvestingPro points to an overbought RSI but still considers the stock undervalued relative to its fair value. The company beat expectations in Q1 2026 with adjusted EPS of $0.54 (expectation $0.40) and revenue of $392 million (expectation $381.81 million). » Mere på de.investing.com
Integra: Q1 profit jump pushes full-year forecast higher
Integra reported adjusted earnings per share of $0.54 in Q1 (expectation $0.40) and revenue of $391.9m, both above consensus. Strong margins and operational execution led to an increase in the full-year adjusted EPS guidance to $2.40–2.50, while the revenue outlook of $1.662–1.702bn remains confirmed. Adjusted EBITDA margin rose markedly, while net debt of $1.6bn and weak free-cash-flow conversion continue to pose risks. Management sees further growth from product demand, supply-chain stabilization and tariff effects, but remains confronted with execution risks. » Mere på de.investing.com
Integra LifeSciences significantly beats Q1 forecasts and raises full-year guidance
Integra LifeSciences reported adjusted EPS of $0.54 for Q1 2026 versus an expected $0.40 and revenue of $392 million (forecast $381.81 million). Gross margin and adjusted EBITDA margin improved markedly, and operating income and cash flow also increased. The company raised its full-year EPS guidance to $2.40–$2.50 and cited product innovations, operational efficiency and the reopening of sites as growth drivers. The stock jumped sharply in pre-market trading but later closed above the prior close. » Mere på de.investing.com
Virksomhedstal
I det seneste kvartal havde Integra Lifescience. en omsætning på 363,01 mio. € og et nettoresultat på 13,11 mio. €
| (EUR) | september 2026 | YoY |
|---|---|---|
| Omsætning | 363,01 mio. | 5,96 % |
| Bruttofortjeneste | 185,28 mio. | 3,84 % |
| Nettoresultat | 13,11 mio. | 384,74 % |
| EBITDA | 34,1 mio. | 26,47 % |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 939,48 mio. € |
Antal aktier | 77,8 mio. |
Højeste/laveste i 52 uger | 18,67 € - 7,93 € |
| Udbytte | Nej |
Beta | 1,28 |
P/E (PE Ratio) | 78,96 |
PEG (PEG Ratio) | 0,12 |
K/I (PB Ratio) | 0,98 |
P/S (PS Ratio) | 0,62 |
Virksomhedsprofil
Integra LifeSciences Holdings Corporation udvikler, fremstiller og markedsfører kirurgiske implantater og medicinske instrumenter til brug i neurokirurgi, rekonstruktion af ekstremiteter og almen kirurgi. Virksomheden opererer i to segmenter, Codman Specialty Surgical og Tissue Technologies. Selskabet tilbyder produkter til neurokirurgi og neurologisk intensivbehandling, herunder udstyr til vævsablation, produkter til reparation af dura, enheder til håndtering af cerebrospinalvæske, udstyr til intrakraniel monitorering og udstyr til kranial stabilisering; samt kirurgiske pandelamper og instrumenter, samt software og support til aktivhåndtering og eftermarkedsservice. Virksomheden sælger desuden ca. 40.000 instrumentmønstre samt kirurgiske produkter og belysningsprodukter til hospitaler og kirurgiske centre, samt til tandlæge-, fodterapeut- og dyrlægeklinikker. Derudover leverer selskabet regenerative teknologiprodukter til behandling af akutte og kroniske sår, og kirurgiske vævsreparationsprodukter til brok-operationer, reparation og beskyttelse af perifere nerver samt senereparation. Endvidere tilbyder det produkter til hud- og sårreparation, plastik- og kirurgisk rekonstruktion, knogletransplantater og produkter til nerve- og senereparation. Selskabet udbyder sine produkter direkte gennem forskellige salgsstyrker og andre distributionskanaler til hospitaler, integrerede sundhedsnetværk, indkøbsorganisationer, klinikere, kirurgiske centre og sundhedsudbydere i USA, Europa, Asien-Stillehavsområdet og internationalt. Integra LifeSciences Holdings Corporation blev stiftet i 1989 og har hovedkvarter i Princeton, New Jersey.
| Navn | Integra Lifescience. |
| CEO | Stuart Essig |
| Hjemsted | Princeton,
nj USA |
| Websted | |
| Sektor | Cykliske forbrugsvarer |
| Branche | Forbrugsgoder |
| Børsnotering | 16.08.1995 |
| Medarbejdere | 4.427 |
Tickersymboler
| Børs | Symbol |
|---|---|
NASDAQ | IART |
Frankfurt | IL3.F |
Düsseldorf | IL3.DU |
SIX | IL3.SW |
München | IL3.MU |